FKC-289

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameFKC-289
Drug Alias NameFKC289FKC-289
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsAmyloidosisNephrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFosun Kairos (Shanghai) Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFosun Kairos (Shanghai) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsAmyloidosisNephrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A